Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Adenocarcinoma

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a transcription factor implicated in cancer and metabolic disorders.
• PPAR-γ ligands exhibit anti-tumorigenic properties in prostate cancer, showing anti-proliferative and pro-differentiation effects.

Purpose of the Study:

• To validate PPAR-γ expression in malignant and benign prostate tissues using immunohistochemistry and quantitative real-time PCR.
• To investigate the localization and expression levels of PPAR-γ in prostate adenocarcinoma.

Main Methods:

• Immunohistochemistry was performed on 730 prostate adenocarcinomas (PCAs) and 25 benign prostate tissues using two PPAR-γ antibodies.
• Quantitative real-time PCR was used to assess PPAR-γ mRNA expression in a subset of benign and malignant prostate tissues.
• Analysis correlated PPAR-γ expression with Gleason score, pathologic stage, and tissue type.

Main Results:

• Cytoplasmic PPAR-γ immunoreactivity was observed in 10.7% of PCAs, with no nuclear immunoreactivity detected in malignant tissues.
• Benign prostate tissues showed predominantly negative PPAR-γ immunoreactivity, with some weak cytoplasmic staining and nuclear staining in specific epithelial regions.
• Constitutive PPAR-γ mRNA levels were significantly lower in PCAs compared to benign tissues.
• No significant association was found between PPAR-γ mRNA levels or cytoplasmic staining and Gleason score, grade, or pathologic stage.

Conclusions:

• The study supports evidence for extra-nuclear localization and potential non-genomic actions of PPAR-γ in prostate cancer.
• Reduced PPAR-γ expression in prostate cancer suggests a potential role in tumorigenesis.
• Further research is warranted to elucidate the functional role and therapeutic implications of PPAR-γ in prostate cancer.